Pulmonary fibrosis treatment Ofev (nintedanib) slows the progression of fibrosis lesions, according to high-resolution scans used in a Phase 3b clinical trial.

Computed tomography imaging demonstrated for the first time that six months of Ofev could reduce  the progression of patients’ lung fibrosis lesions, compared with a placebo. Two previous Phase 3 trials have also shown the therapy’s effectiveness. Researchers presented the Phase 3b trial results at the Pulmonary Fibrosis Foundation Summit 2017.

“With the aid of high-resolution CT scans, we have observed a reduction in the progression of lung fibrosis with Ofev versus placebo,” Dr Lisa Lancaster, clinical director of the Interstitial Lung Disease Program at Vanderbilt University Medical Center, said in a press release.